Feb 2 2011
Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com. Research 2.0 is pioneering a new "open professional" model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.
"We'll let the report and the Research 2.0 analysts speak for themselves, but suffice it to say that we're very happy to reach a new audience with a professional analysis and evaluation of the company at the same time that we've successfully transitioned from a preclinical to clinical stage biotech company," said Viral Genetics CEO Haig Keledjian.
Research 2.0's principals have over 50 years combined experience in traditional investment banking research and portfolio management, including the managing of a five hundred million dollar biotech investment management fund. The firm provides research coverage and advisory services to over two-dozen small, technology-focused public and private companies in a variety of sectors including life sciences, software, cloud computing and other technologies. Their research reports on clients are available through FactSet, CapitalIQ, and TheMarkets.com, as well as through subscription services. Additionally, over 12,000 individual investors, media, investment professionals and others subscribe to the Research 2.0 blog where founder and CEO, Kris Tuttle, writes additional updates and more informal notes about clients, the markets and other topics, available at http://blog.research2zero.com and syndicated to www.seekingalpha.com.